TNFRSF8 and neoplasm: Lots of aspects might contribute to the anti-CD30 therapy, such as the mechanism anti-CD30 of ENKTL and bystander killing phenomenon (neighborhood cells which are negative in CD30 surrounding the CD30 positive tumor cells also be killed since the CD30 positive neoplastic cells secret CD30-expressing extracellular vesicles binding to CD30 ligands on bystander cells) [39, 40].